Modus CEO Says Rare Disease Priority Review Voucher To Be Key Catalyst
The US FDA gives Sweden's privately held Modus Therapeutics rare pediatric disease designation for sickle cell disease.
The US FDA gives Sweden's privately held Modus Therapeutics rare pediatric disease designation for sickle cell disease.